A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer

March 19, 2023 updated by: Chongqing University Cancer Hospital
In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.A retrospective study was conducted to explore the influence of 5 factors on PFS in patients with locally advanced cervical cancer receiving radiotherapy and chemotherapy.

Study Overview

Status

Completed

Conditions

Detailed Description

In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.5 factors included positive iliac lymph nodes, histological type, tumor size, positive pelvic lymph nodes on both sides, and maximum lymph node diameter greater than 1cm. Different factors give different scores.If the score is higher than 3, the probability of retroperitoneal lymph node metastasis in patients with locally advanced cervical cancer is significantly increased, and the prognosis of patients is affected. Patients with locally advanced cervix receiving radical radiotherapy were scored based on 5 factors.Patients with scores greater than or equal to 3 points were compared with patients with scores less than 3 points.

Study Type

Observational

Enrollment (Actual)

183

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Chongqing
      • Chongqing, Chongqing, China, 400030
        • Chongqing Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

From May 2016 to July 2021, 183 patients with locally advanced cervical cancer received radiotherapy in our hospital ,with or without chemotherapy.Patients were scored according to 5 factors. PFS were compared between patients with scores greater than or equal to 3 points and those with scores less than 3 points. PFS is defined as the time from the end of treatment to disease progression or the time of the last follow-up 2022-10-01.

Description

Locally advanced cervical cancer patients receiving radiotherapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Scores greater than or equal to 3 in patients with locally advanced cervical cancer
Patients with locally advanced cervical cancer scored less than 3 points
Patients receiving radiotherapy for locally advanced cervical cancer were scored according to five factors, with a score of less than 3

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression Free Survival（PFS）
Time Frame: 3 months
Whether there are differences in PFS between the two groups
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chongqing University Cancer Hospital

Investigators

  • Study Director: Zou Dongling, M.D., Chongqing University Cancer Hospital Chongqing, Chongqing, China,

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 10, 2022

Primary Completion (Actual)

November 1, 2022

Study Completion (Actual)

December 10, 2022

Study Registration Dates

First Submitted

February 19, 2023

First Submitted That Met QC Criteria

March 19, 2023

First Posted (Actual)

March 22, 2023

Study Record Updates

Last Update Posted (Actual)

March 22, 2023

Last Update Submitted That Met QC Criteria

March 19, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CQGOG0111

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Radiotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe